The stiffness of tissue shapes how cancer spreads
In the long effort to understand why two patients with the same breast cancer diagnosis can face such different fates, Spanish researchers have identified the stiffness of the tumor's surrounding tissue—a process called fibrosis—as a meaningful predictor of how aggressively the disease will behave. Working with a gene-sequencing diagnostic tool called MeCo Score®, a team at Spain's National Cancer Research Center found that patients with high-fibrosis HER2-negative tumors responded particularly well to the addition of nintedanib, a drug already used to treat lung scarring, alongside standard chemotherapy. The study, published in Clinical Cancer Research, suggests that medicine's next frontier in breast cancer may lie not in the tumor cell itself, but in the hardened scaffold surrounding it.
- HER2-negative breast cancer carries a deceptive uniformity—its single label conceals wildly different outcomes that oncologists have struggled for years to anticipate.
- Tumor fibrosis, long treated as background scenery, has now been confirmed in a clinical study as a powerful driver of metastasis and relapse, raising the stakes for how risk is assessed.
- A 1,000-gene diagnostic test called MeCo Score® can now quantify fibrosis levels in early-stage tumors, giving clinicians a concrete tool to sort patients by risk before treatment begins.
- Nintedanib—repurposed from pulmonary fibrosis—showed its strongest anti-cancer effect precisely in the patients MeCo Score® flagged as high-fibrosis, validating a personalized treatment pairing.
- The path forward requires FDA approval and far larger patient datasets, but the study already stands as proof that the right diagnostic test can breathe new life into an existing drug.
Most women diagnosed with breast cancer have the HER2-negative form, yet beneath that shared label lies enormous variation in how the disease unfolds. Oncologists have long struggled to predict who will relapse and who will not—until now, a crucial clue may have been hiding in the tissue surrounding the tumor itself.
Researchers led by Miguel Ángel Quintela at Spain's National Cancer Research Center have confirmed, for the first time in a clinical study, that fibrosis—the hardening of the extracellular matrix around tumor cells—is a powerful predictor of aggressive behavior in HER2-negative breast cancer. The finding, published in Clinical Cancer Research, reframes how doctors might approach risk stratification in this common cancer type.
At the center of the research is MeCo Score®, a diagnostic tool developed by a University of Arizona spinoff that sequences roughly 1,000 genes in early-stage tumor tissue to measure fibrosis levels. Higher scores signal greater fibrosis and a correspondingly higher risk of relapse or spread—but the test does more than measure risk. It also points toward a treatment strategy.
That strategy involves nintedanib, a drug currently used to treat idiopathic pulmonary fibrosis. When Quintela's team combined it with standard chemotherapy and analyzed biopsy samples from 73 patients using MeCo Score®, the results were striking: patients with higher baseline fibrosis benefited most from nintedanib's addition. The collaboration grew from a decade-old clinical trial Quintela's group had conducted with roughly 130 breast cancer patients—the only study of its kind when researchers at the University of Arizona Cancer Center came looking.
The implications point toward a more tailored approach: rather than applying the same chemotherapy regimen to all HER2-negative patients, oncologists could use MeCo Score® to identify those who would genuinely benefit from nintedanib, sparing others unnecessary exposure and cost. FDA approval of the test would require data from many more patients, but the study already demonstrates that a drug born in one disease can, paired with the right diagnostic, open unexpected doors in another.
Most women diagnosed with breast cancer have the HER2-negative form—the most common subtype, defined by low levels of a growth-promoting protein called HER2. Yet beneath this single label lies enormous variation. Two patients with identical diagnoses can follow wildly different disease trajectories, and oncologists have long struggled to predict who will relapse and who will remain disease-free. A team at Spain's National Cancer Research Center may have found a crucial piece of the puzzle: the stiffness of the tissue surrounding tumor cells.
The extracellular matrix—the structural scaffolding that holds tumor cells in place—can harden through a process called fibrosis. This hardening, it turns out, is not merely a passive feature of the tumor landscape. Researchers led by Miguel Ángel Quintela have now confirmed, for the first time in a clinical study, that the degree of fibrosis in HER2-negative breast tumors is a powerful predictor of how aggressively the cancer will behave. Tumors with more fibrosis are more likely to metastasize and recur. The finding, published in Clinical Cancer Research, reframes how doctors might think about risk stratification in this common cancer type.
The research centers on a new diagnostic tool called MeCo Score®, developed by the company MeCo Diagnostics, a spinoff of the University of Arizona. The test sequences roughly 1,000 genes in early-stage tumor tissue and focuses specifically on those whose activity correlates with fibrosis. The resulting score creates a scale: higher scores indicate greater fibrosis and, correspondingly, higher risk of relapse or spread. But the test does more than measure risk. It also points toward a treatment strategy.
The drug in question is nintedanib, currently used to treat idiopathic pulmonary fibrosis, a scarring disease of the lungs. Quintela's team discovered that when nintedanib is added to standard chemotherapy, it appears to slow or prevent fibrosis in breast tumors—and in doing so, improves outcomes. This marks the first time an anti-fibrotic drug has shown potent activity against cancer itself. The finding emerged from a collaboration that began a decade earlier, when Quintela's group had treated roughly 130 breast cancer patients with nintedanib in a 2014 study. When researchers at the University of Arizona Cancer Center, led by Gus Mouneimne, began investigating nintedanib's ability to reduce tumor fibrosis, they discovered that Quintela's work was the only clinical trial of its kind in existence.
The two teams joined forces. Quintela's group retrieved biopsy samples from 73 patients—taken both before and after treatment with nintedanib plus chemotherapy—and analyzed them using MeCo Score®. The results were striking: patients whose tumors showed higher baseline fibrosis benefited most from the addition of nintedanib. In other words, the test could identify which patients would respond best to this combination approach, enabling a more tailored treatment plan.
The implications are significant. Rather than giving all HER2-negative breast cancer patients the same chemotherapy regimen, oncologists could use MeCo Score® to identify those with high-fibrosis tumors and offer them nintedanib as an addition to their standard care. This approach promises to be both more effective and more economical—patients who don't need the extra drug avoid unnecessary exposure and cost. Quintela notes that the next step would be seeking FDA approval for MeCo Score®, though that would require data from many more patients. For now, the study stands as proof that a drug developed for one disease can, when paired with the right diagnostic test, unlock new possibilities in another.
Citações Notáveis
For the first time in a clinical study, the role of fibrosis as a very adverse negative prognostic factor has been confirmed.— Miguel Ángel Quintela, Spanish National Cancer Research Center
This strategy defines a pathway toward more personalized and lower-cost treatment paradigms for breast cancer and represents the first successful clinical application targeting tumor fibrosis in oncology.— Study authors
A Conversa do Hearth Outra perspectiva sobre a história
Why does the stiffness of tissue around a tumor matter so much? It seems like a detail.
Because stiffness changes how cells behave. A rigid matrix makes it harder for the immune system to reach the tumor, and it can actually push cancer cells toward spreading. It's not just a detail—it's a physical property that shapes the entire disease.
And this nintedanib drug—it was designed for lungs, not cancer. How did anyone think to try it here?
Quintela's team had already used it in a 2014 breast cancer trial. When the Arizona researchers started looking at fibrosis specifically, they found his work and realized they had a rare clinical dataset. It was less about inspiration and more about recognizing what they already had.
So the test predicts who will benefit from the drug?
Exactly. The MeCo Score® measures fibrosis, and the higher the score, the more likely a patient is to respond well to nintedanib plus chemotherapy. It's personalization based on tumor biology, not guesswork.
What happens to patients with low-fibrosis tumors?
They probably don't need nintedanib. Standard chemotherapy may be sufficient. That's the efficiency gain—you're not exposing everyone to an extra drug if they won't benefit from it.
Is this ready for doctors to use?
Not yet. They need FDA approval for the test, and that requires data from many more patients than the 73 they analyzed. This study is proof of concept, not a finished product.